ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma.

Aditi Mulgaonkar Roy Elias Layton Woolford Bing Guan Kien Nham Payal Kapur Alana Christie Vanina Toffessi Tcheuyap Nirmish Singla Isaac Alex Bowman Christina Stevens Guiyang Hao James Brugarolas Xiankai Sun

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

ImmunoPET with [89Zr]Zr-DFO-ATZ may enable a thorough and dynamic assessment of PD-L1 across sites of disease. The power of immunoPET to predict ICI response in RCC is being explored in an ongoing clinical trial (NCT04006522).

Keyphrases

pet imaging
renal cell carcinoma
clinical trial
high resolution
positron emission tomography
randomized controlled trial
computed tomography
photodynamic therapy
pet ct